Novartis AG Expected to Earn FY2020 Earnings of $5.71 Per Share (NYSE:NVS)

Novartis AG (NYSE:NVS) – Equities researchers at Jefferies Financial Group dropped their FY2020 EPS estimates for Novartis in a research note issued on Tuesday, October 15th. Jefferies Financial Group analyst P. Welford now forecasts that the company will earn $5.71 per share for the year, down from their previous estimate of $5.77. Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Novartis’ FY2021 earnings at $6.44 EPS, FY2022 earnings at $7.06 EPS and FY2023 earnings at $7.44 EPS.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, July 18th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.20 by $0.14. The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Novartis had a return on equity of 18.55% and a net margin of 23.27%. The firm’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.29 EPS.

Several other research firms have also recently commented on NVS. ValuEngine upgraded Novartis from a “sell” rating to a “hold” rating in a report on Saturday. JPMorgan Chase & Co. restated a “sell” rating on shares of Novartis in a report on Friday, July 5th. Argus lifted their price target on Novartis to $105.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. They noted that the move was a valuation call. Kepler Capital Markets cut Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Zacks Investment Research cut Novartis from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a report on Friday, July 19th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $93.29.

NVS opened at $86.88 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.74. The stock has a market capitalization of $199.91 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 1.96 and a beta of 0.59. The business has a 50-day moving average of $87.35 and a two-hundred day moving average of $87.62. Novartis has a 12 month low of $72.19 and a 12 month high of $95.00.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVS. Asset Dedication LLC lifted its stake in shares of Novartis by 98.7% in the 2nd quarter. Asset Dedication LLC now owns 304 shares of the company’s stock valued at $27,000 after purchasing an additional 151 shares in the last quarter. Moneta Group Investment Advisors LLC lifted its stake in shares of Novartis by 795.8% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 2,750 shares of the company’s stock valued at $27,000 after purchasing an additional 2,443 shares in the last quarter. Vigilant Capital Management LLC acquired a new position in shares of Novartis in the 2nd quarter valued at about $37,000. Anderson Fisher LLC acquired a new position in shares of Novartis in the 2nd quarter valued at about $39,000. Finally, Manchester Financial Inc. acquired a new position in shares of Novartis in the 2nd quarter valued at about $45,000. 11.18% of the stock is currently owned by institutional investors and hedge funds.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Story: Understanding Market Liquidity

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.